REN and hydrops fetalis: There are trials confirming or contradicting the role of beta-blockers and inhibitors of the renin–angiotensin–aldosterone system (RAAS) in the prevention of primary anthracycline cardiotoxicity, especially in patients without classic risk factors for HF.